2022 World Conference on Lung Cancer (ePosters)-EP08.02-069. A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases

EP08.02-069. A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases

Back to course

Pdf Summary

In this retrospective study conducted in China, the effectiveness of aumolertinib, a novel third-generation EGFR-TKI, was evaluated in the treatment of patients with leptomeningeal metastases (LM) caused by EGFR-mutated non-small-cell lung cancer (NSCLC). The incidence of brain metastases in NSCLC patients is relatively low, but higher in those with EGFR mutations. However, the survival rate for patients with NSCLC and LM is generally poor, with a median overall survival of 3-10 months.<br /><br />Previous trials have shown that double dose third-generation EGFR-TKIs have been effective in treating brain and leptomeningeal metastases in EGFR-mutant NSCLC patients. Aumolertinib has shown promising results in preclinical studies with its ability to penetrate the blood-brain barrier. The AENEAS trials also demonstrated its efficacy in patients with advanced EGFR-mutant NSCLC.<br /><br />The study included 11 patients with a median age of 60.5 years. Most patients were non-smokers and had EGFR exon 21 L858R mutations. Prior treatments included brain radiotherapy, EGFR-TKI therapy, and chemotherapy. The patients were treated with aumolertinib either as monotherapy or in combination with other therapies. The evaluation of the best overall response showed partial responses and stable disease in most patients, with a median progression-free survival of 8.1 months.<br /><br />Adverse events were reported in all patients, but only one patient experienced a grade 3 adverse event and one patient had a serious adverse event. No adverse events led to treatment discontinuation or death.<br /><br />In conclusion, aumolertinib monotherapy or combination therapy demonstrated superior activity in treating leptomeningeal metastases in patients with advanced EGFR-mutated NSCLC. However, further studies with larger sample sizes are needed to investigate the role of aumolertinib in this patient population. The study was sponsored by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Asset Subtitle

siyuan Huang

Meta Tag

Speaker siyuan Huang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

China

retrospective study

aumolertinib

third-generation EGFR-TKI

leptomeningeal metastases

EGFR-mutated non-small-cell lung cancer

brain metastases

survival rate

AENEAS trials

adverse events